scholarly journals Comparison of Breast Cancer 3-years Survival Rate Based on the Pathological Stages

2019 ◽  
Vol 10 (1) ◽  
pp. 38
Author(s):  
Nur Imroatul Mursyidah ◽  
Ami Ashariati ◽  
Etty Hary Kusumastuti
Keyword(s):  
Breast Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
General Hospital ◽  
Cancer Survival ◽  
Stage Iv ◽  
Secondary Data ◽  
Breast Cancer Survival ◽  
Breast Cancer Patients ◽  
Retrospective Case

ABSTRACTIntroduction: The aims of this study was to determine the differences of  breast cancer survival rate based on Pathological stages.Methods: This study was conducted with a retrospective case control design using secondary data from Dr. Soetomo General Hospital's medical records. The technique used to take the samples was purposive sampling. The sample was 45 breast cancer patients in Dr. Soetomo General Hospital In January 2015, that able to be contacted again and had a medical record in the oncology center in Dr. Soetomo General Hospital Surabaya. The variables studied is breast cancer survival based on the pathological stages.Results: Breast cancer patients at the stage of IIA have 100% 3-year survival rate, stage IIB by 83.3%, stage IIIA by 71.4%, stage IIIB by 53.8%, IIIC by 50%, and stage IV by 30%. With a comparison of the log-rank significance p = 0.104.Conclusion: The survival rate of breast cancer patients is lower in line with the increasing pathological stage of breast cancer.

scholarly journals The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Danny Houtsma ◽  
Stefanie de Groot ◽  
Renee Baak-Pablo ◽  
Elma Meershoek -Klein Kranenbarg ◽  
Caroline M. Seynaeve ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Early Breast Cancer ◽  
Cancer Survival ◽  
Breast Cancer Survival ◽  
Breast Cancer Patients ◽  
Available N ◽  
Cox Regression Analysis ◽  
Breast Cancer Outcome

AbstractThe PvuII (rs2234693) Single Nucleotide Polymorphism (SNP) in the gene coding for the estrogen receptor-1 (ESR1), has been found associated with outcome in tamoxifen treated patients with early hormone-receptor positive breast cancer. However, it remains unclear whether this SNP is a predictive marker for tamoxifen efficacy or a prognostic marker for breast cancer outcome. The aim of this study was to examine the prognostic potential of this SNP in postmenopausal early breast cancer patients treated with adjuvant exemestane. Dutch postmenopausal patients randomised to 5 years of adjuvant exemestane of whom tissue was available (N = 807) were selected from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial database. The SNP rs2234693 in the ESR1 gene was genotyped on DNA from formalin-fixed paraffin embedded (FFPE) tumor tissue using Taqman assays and related to the primary endpoint disease-free survival (DFS) and secondary endpoint overall survival (OS). Survival analyses were performed using Cox regression analysis. In total 805 patients were included in the analyses (median follow up of 5.22 years) and genotypes were obtained in 97% of the samples. The variant T allele of PvuII in ESR1 (rs2234693) was associated with a better DFS (hazard ratio (HR) 0.689, 95% confidence interval (CI) 0.480–0.989, P = 0.044) in univariate analysis only, and a better OS in both univariate (HR 0.616, 95%, CI 0.411–0.923, P = 0.019) and multivariate analyses (HR 0.571, 95% CI 0.380–0.856, P = 0.007), consistent with a prognostic rather than a predictive drug response effect. Variation of PvuII in the ESR1 gene is related to OS in postmenopausal, early HR + breast cancer patients treated with exemestane in the TEAM study. Variation in the ESR1 gene may therefore be a prognostic marker of early breast cancer survival, and warrants further research.

scholarly journals Changing Trends of Breast Cancer Survival in Sultanate of Oman

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Shiyam Kumar ◽  
Ikram A. Burney ◽  
Adel Al-Ajmi ◽  
Mansour S. Al-Moundhri
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Survival ◽  
Survival Rates ◽  
Breast Cancer Survival ◽  
Lymph Node Status ◽  
Skin Involvement ◽  
Sultanate Of Oman ◽  
Breast Cancer Patients ◽  
Free Survival

Breast cancer is the leading cause of cancer-associated mortality in women, with elevated incidence in developing countries. This retrospective study included all 122 patients diagnosed with breast cancer from January 2003 to December 2008 in the Sultanate of Oman. Age at presentation was 47.41 years (SD12.88), with one-third of patients younger than 40 years. The majority of patients presented with stage III (41.2%) and IV (18.2%) breast cancer. T size (), skin involvement (), and stage at presentation () were significantly associated with overall survival. Skin involvement at presentation (), T size (), lymph node status (), and stage () were strong predictors of relapse-free survival. Patients had a 5-year survival of 78%, compared to 64% of breast cancer patients diagnosed between 1996 and 2002 identified in our previously published study. Thus, despite Omani breast cancer patients continuing to present with advanced breast cancer, survival rates have significantly improved.

scholarly journals Gambaran komponen sindrom metabolik pada pasien kanker payudara di RSUP Prof. Dr. R. D. Kandou Manado tahun 2014 – 2015

e-CliniC ◽  
2016 ◽  
Vol 4 (2) ◽  
Author(s):  
Kartika Wowor ◽  
Harlinda Haroen ◽  
Karel Pandelaki
Keyword(s):  
Breast Cancer ◽  
Metabolic Syndrome ◽  
Family History ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Stage Iv ◽  
Secondary Data ◽  
Breast Cancer Patients ◽  
Low Level ◽  
History Of

Abstract: Metabolic syndrome (MetS) is estimated to become an important factor for the development of certain types of cancer and their mortality inter alia breast cancer. This was a descriptive retrospective study based on secondary data of medical records of breast cancer patients at Prof. Dr. R. D. Kandou Manado Hospital in 2014-2015. The results showed that the most common components of MetS in breast cancer cases were low level of HDL in 67 cases (68%). One component of MetS was found in 46 cases (64%); 3components of MetS in 6 cases (8%); and 4 components of MetS in 8 cases (11%). Family history of cancer was found in 3 cases with breast cancer (1%). Family history of MetS was found in 3 cases; 1 case of hypertension (0.25%) and 2 cases of hypertension and diabetes (0.50%). The most common clinical stage that had MetS components was stage IV in 27 cases (46%). Conclusion: Most breast cancer patients with MetS components had low level of HDL, only had 1 MetS component, family history of breast cancer and some components of MetS, and in clinical stage IV.Keywords: breast cancer, metabolic syndrome Abstrak: Sindrom metabolik diperkirakan menjadi faktor penting perkembangan jenis kanker tertentu dan mortalitasnya, termasuk peningkatan risiko kanker payudara. Jenis penelitian ialah deskriptif retrospektif berdasarkan data sekunder dari catatan rekam medis pasien kanker payudara di RSUP Prof. Dr. R. D. Kandou Manado tahun 2014-2015. Hasil penelitian memperlihatkan komponen SM yang sering ditemukan ialah kadar HDL rendah berjumlah 67 kasus (68%). Kasus yang memiliki 1 komponen yang memenuhi kriteria SM berjumlah 46 data (64%), 3 komponen berjumlah 6 data (8%) dan 4 komponen berjumlah 8 data (11%). Riwayat penyakit keluarga yang menderita kanker didapatkan tiga kasus dengan kanker payudara (1%). Riwayat penyakit keluarga yang mengalami komponen sindrom metabolik pada tiga kasus; satu kasus dengan hipertensi (0,25%) dan dua kasus dengan hipertensi dan diabetes (0,50%). Stadium klinis yang paling sering memiliki komponen sindrom metabolik ialah stadium IV sebanyak 27 kasus (46%). Simpulan: pada sebagian besar pasien kanker payudara yang memiliki komponen SM ditemukan kadar HDL rendah, hanya memiliki 1 komponen SM, riwayat penyakit keluarga berupa kanker payudara dan beberapa komponen sindrom metabolik, serta stadium klinis IV. Kata kunci: kanker payudara, sindrom metabolik

scholarly journals Does Survival Vary for Breast Cancer Patients in the United States? A Study from Six Randomly Selected States

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Hafiz M. R. Khan ◽  
Lisaann S. Gittner ◽  
Abhilash Perisetti ◽  
Anshul Saxena ◽  
Aamrin Rafiq ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
American Indians ◽  
Survival Data ◽  
Cancer Survival ◽  
Stage Iv ◽  
The United States ◽  
Breast Cancer Patients ◽  
Survival Times ◽  
Age Of Diagnosis

Background. Breast cancer is the most common cancer in women. Disparities in some characteristics of breast cancer patients and their survival data for six randomly selected states in the US were examined. Materials and Methods. A probability random sampling method was used to select the records of 2,000 patients from each of six randomly selected states. Demographic and disease characteristics were extracted from the Surveillance Epidemiology and End Results (SEER) database. To evaluate relationships between variables, we employed a Cox Proportional Regression to compare survival times in the different states. Results. Iowa had the highest mean age of diagnosis at 64.14 years (SE=0.324) and Georgia had the lowest at 57.97 years (SE=0.313). New Mexico had the longest mean survival time of 189.09 months (SE=20.414) and Hawaii the shortest at 119.01 (SE=5.394) months, a 70.08-month difference (5.84 years). Analysis of stage of diagnosis showed that the highest survival times for Whites and American Indians/Alaska Natives were for stage I cancers. The highest survival times for Blacks varied. Stage IV cancer consistently showed the lowest survival times. Conclusions. Differences in breast cancer characteristics across states highlight the need to understand differences between the states that result in variances in breast cancer survival.

scholarly journals MAT2A Localization and Its Independently Prognostic Relevance in Breast Cancer Patients

2021 ◽  
Vol 22 (10) ◽  
pp. 5382
Author(s):  
Pei-Yi Chu ◽  
Hsing-Ju Wu ◽  
Shin-Mae Wang ◽  
Po-Ming Chen ◽  
Feng-Yao Tang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Survival Rate ◽  
Protein Expression ◽  
Cancer Patients ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Breast Cancer Cell Lines ◽  
Breast Cancer Patients ◽  
Expression Ratio

(1) Background: methionine cycle is not only essential for cancer cell proliferation but is also critical for metabolic reprogramming, a cancer hallmark. Hepatic and extrahepatic tissues methionine adenosyltransferases (MATs) are products of two genes, MAT1A and MAT2A that catalyze the formation of S-adenosylmethionine (SAM), the principal biological methyl donor. Glycine N-methyltransferase (GNMT) further utilizes SAM for sarcosine formation, thus it regulates the ratio of SAM:S-adenosylhomocysteine (SAH). (2) Methods: by analyzing the TCGA/GTEx datasets available within GEPIA2, we discovered that breast cancer patients with higher MAT2A had worse survival rate (p = 0.0057). Protein expression pattern of MAT1AA, MAT2A and GNMT were investigated in the tissue microarray in our own cohort (n = 252) by immunohistochemistry. MAT2A C/N expression ratio and cell invasion activity were further investigated in a panel of breast cancer cell lines. (3) Results: GNMT and MAT1A were detected in the cytoplasm, whereas MAT2A showed both cytoplasmic and nuclear immunoreactivity. Neither GNMT nor MAT1A protein expression was associated with patient survival rate in our cohort. Kaplan–Meier survival curves showed that a higher cytoplasmic/nuclear (C/N) MAT2A protein expression ratio correlated with poor overall survival (5 year survival rate: 93.7% vs. 83.3%, C/N ratio ≥ 1.0 vs. C/N ratio < 1.0, log-rank p = 0.004). Accordingly, a MAT2A C/N expression ratio ≥ 1.0 was determined as an independent risk factor by Cox regression analysis (hazard ratio = 2.771, p = 0.018, n = 252). In vitro studies found that breast cancer cell lines with a higher MAT2A C/N ratio were more invasive. (4) Conclusions: the subcellular localization of MAT2A may affect its functions, and elevated MAT2A C/N ratio in breast cancer cells is associated with increased invasiveness. MAT2A C/N expression ratio determined by IHC staining could serve as a novel independent prognostic marker for breast cancer.

scholarly journals Stage-Specific Survival Rate of Breast Cancer Patients in Northern Thailand in Accordance with Two Different Staging Systems

2019 ◽  
Vol 20 (9) ◽  
pp. 2699-2706
Author(s):  
Imjai Chitapanarux ◽  
Patumrat Sripan ◽  
Areewan Somwangprasert ◽  
Chaiyut Charoentum ◽  
Wimrak Onchan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Northern Thailand ◽  
Staging Systems
Sign in / Sign up

Export Citation Format

Share Document